Noguchi Tsuyoshi, Fujiwara Shozo, Takeno Shinsuke, Kai Shinya, Mizuta Akari, Nagao Yuko, Uchida Yuzo
Department of Oncological Science (Surgery II), Oita Medical University, Isaigaoka 1-1, Hasama-machi, Oita 879-5593, Japan.
Oncol Rep. 2003 May-Jun;10(3):561-6.
Thymidine phosphorylase (dThdPase) is an enzyme that is involved in pyrimidine nucleoside metabolism and DNA synthesis and converts 5'-deoxy-5-fluorouridine (5'-DFUR) to 5-fluorouracil (5-FU). The aim of this study was to elucidate the relationship between dThdPase expression and biological malignancy, prognosis, and sensitivity to postoperative chemotherapy, using immunohistochemical staining. We studied 148 patients with gastric cancer who underwent surgery at Department of Surgery II in Oita Medical University between 1990 and 1999. Immunohistochemical expression of dThdPase was correlated to clinicopathological factors and postoperative survival. Tumor tissue was dThdPase-positive in 112 patients. The results suggested a relationship between the degree of histological differentiation and dThdPase expression (p=0.0697). Examination of dThdPase expression based on the site of the tumor revealed that the groups with upper or lower gastric cancer included a significantly greater number of dThdPase-positive patients (p=0.0011). Analysis of the patients as a whole showed no significant difference between the survival. In the chemotherapy group, the dThdPase-positive patients tended to have a more favorable prognosis than the dThdPase-negative patients (p=0.0578). The results suggest that postoperative adjuvant chemotherapy that makes use of FU metabolic pathways may improve prognosis in patients with dThdPase-positive gastric cancer.
胸苷磷酸化酶(dThdPase)是一种参与嘧啶核苷代谢和DNA合成的酶,可将5'-脱氧-5-氟尿苷(5'-DFUR)转化为5-氟尿嘧啶(5-FU)。本研究旨在通过免疫组织化学染色阐明dThdPase表达与生物学恶性程度、预后以及对术后化疗敏感性之间的关系。我们研究了1990年至1999年间在大分医科大学第二外科接受手术的148例胃癌患者。dThdPase的免疫组织化学表达与临床病理因素及术后生存率相关。112例患者的肿瘤组织dThdPase呈阳性。结果提示组织学分化程度与dThdPase表达之间存在关联(p = 0.0697)。根据肿瘤部位检查dThdPase表达发现,上胃癌或下胃癌组中dThdPase阳性患者数量显著更多(p = 0.0011)。对所有患者进行分析显示生存率无显著差异。在化疗组中,dThdPase阳性患者的预后往往比dThdPase阴性患者更有利(p = 0.0578)。结果表明,利用FU代谢途径的术后辅助化疗可能改善dThdPase阳性胃癌患者的预后。